Harmony Biosciences obtains exclusive license for orexin-2 receptor agonist from Bioprojet

Harmony Biosciences Holdings, Inc.

Upfront fee $25.5M; development/regulatory milestones up to $127.5M, sales milestones up to $240M.
Licensed compound is pre-clinical; IND expected H2 2025 for narcolepsy and other indications.
Exclusive rights to develop, manufacture, commercialize in US and Latin America.
Amended 2017 and 2022 LCAs with Bioprojet to remove exclusivity of efforts provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.